Physician profile
Anitha S Dhar
NPI 1215902796
$4,392.11
in general payments reported to CMS, 2019-2025
34 companies · $929 in 2025
The $929 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2020: $499 · 2021: $489 · 2022: $691 · 2023: $658 · 2024: $780 · 2025: $929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,367.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $612.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $499.45 | 2020-2025 | Jardiance, Zepbound, Mounjaro |
| Abbvie INC. | $483.70 | 2021-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $460.64 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Esperion Therapeutics, INC. | $245.33 | 2021-2025 | Nexletol |
| Pfizer INC. | $188.70 | 2019-2025 | |
| Allergan, INC. | $179.92 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $175.87 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.90 | 2019-2024 | Jardiance, Synjardy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $149.75 | 2022-2025 | Caplyta |
| Glaxosmithkline, LLC. | $137.16 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Amgen INC. | $129.92 | 2023-2025 | Otezla, Repatha, Evenity |
| Exact Sciences Corporation | $109.18 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.13 | 2019-2025 | Xifaxan, Trulance |
| Shield Therapeutics INC | $97.84 | 2023-2025 | Accrufer |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $77.85 | 2020-2021 | |
| Astellas Pharma US INC | $76.40 | 2020-2025 | Veozah |
| Axsome Therapeutics, INC. | $67.35 | 2025 | Auvelity |
| Advanced Bionics, LLC | $53.70 | 2022 | |
| Supernus Pharmaceuticals, INC. | $52.95 | 2019-2020 | |
| Nevro Corp. | $49.21 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $32.89 | 2021-2022 | |
| Sanofi Pasteur INC. | $32.37 | 2019-2022 | |
| Optinose US, INC. | $26.64 | 2025 | |
| Gilead Sciences, INC. | $26.12 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.14 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.45 | 2022 | |
| Lundbeck LLC | $21.54 | 2025 | Rexulti |
| Abbott Laboratories | $20.23 | 2019 | |
| Phathom Pharmaceuticals, INC. | $19.80 | 2024 | Voquezna |
| Celgene Corporation | $19.61 | 2019 | |
| Amarin Pharma, INC. | $15.38 | 2021 | |
| Endogastric Solutions, INC | $13.93 | 2022 | |
| Eisai INC. | $12.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anitha Dhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.